Today: 20 May 2026
Browse Category

NYSE:MOS 10 October 2025 - 12 March 2026

Mosaic Stock (NYSE: MOS) Slides on Brazil Phosphate Curtailments, Belarus Potash Sanctions Shift, and a Saskatchewan Mine Incident

Mosaic Stock (NYSE: MOS) Slides on Brazil Phosphate Curtailments, Belarus Potash Sanctions Shift, and a Saskatchewan Mine Incident

Mosaic shares fell 5.6% to $23.46 after the company idled SSP fertilizer production at two Brazilian sites due to a sharp sulfur price spike and reported a fatal accident at its K3 mine in Canada. The moves come as U.S. sanctions relief for Belarus potash raised fresh supply concerns, pressuring fertilizer stocks.
17 December 2025
··
Mosaic Company Stock (MOS) News Today: Supply Shock, Analyst Targets, and the 2026 Fertilizer Outlook (Dec. 12, 2025)

Mosaic Company Stock (MOS) News Today: Supply Shock, Analyst Targets, and the 2026 Fertilizer Outlook (Dec. 12, 2025)

Mosaic (NYSE: MOS) rose 3.6% to $26.10 on December 12, 2025, after reports of Ukrainian drone strikes on Russian fertilizer plants triggered supply concerns. The rally followed a broad move in fertilizer stocks amid renewed geopolitical risks. Mosaic’s phosphate winter fill prices for December were set $63–$70 below November averages, signaling softer near-term pricing.
12 December 2025
·
Mosaic Stock Tanks on Fertilizer Shock: Is NYSE:MOS a Buy or Bust in October 2025?

Mosaic Stock Tanks on Fertilizer Shock: Is NYSE:MOS a Buy or Bust in October 2025?

Mosaic shares fell 7–10% to the low $30s on October 10, 2025, after third-quarter phosphate production missed targets. The company also sold an idled Brazil unit for $111 million. Analysts split on the stock: some cut ratings after the output miss, while others upgraded on improved earnings forecasts. Mosaic remains up about 40% year-on-year but is testing key technical support.
10 October 2025
·

Stock Market Today

  • Parabilis Plans IPO to Fund Phase 3 Trial for Tumor Drug Following Regeneron Deal
    May 20, 2026, 5:56 AM EDT. Parabilis Medicines, a Massachusetts biotech, is preparing for an initial public offering (IPO) to finance the phase 3 trial of its tumor drug zolucatetide, targeting rare desmoid tumors. The drug, which inhibits the Wnt/β-catenin pathway implicated in many cancers, recently received FDA fast-track status. Proceeds will also support phase 1 trials for additional cancers. Parabilis secured a $50 million upfront payment and a $75 million equity investment from Regeneron in a deal to explore Parabilis' helicon peptide platform. The firm boasts over $300 million in cash from prior funding rounds. CEO Mathai Mammen aims to grow Parabilis into a fully integrated research, development, manufacturing, and commercialization company, relying on partnerships to finance its ambitions.

Latest articles

San Antonio’s New Battery Bet Comes Just as CPS Outages Get Longer

San Antonio’s New Battery Bet Comes Just as CPS Outages Get Longer

20 May 2026
OCI Energy and CPS Energy have begun building a 120-megawatt battery storage facility in southeastern Bexar County, aiming for commercial operation in 2027. The project follows a rise in average outage duration for CPS Energy customers to 75.38 minutes in 2025. OCI will own the facility, with CPS holding operational control. ING is financing construction, and LG Energy Solution Vertech is supplying batteries.
Co-Diagnostics Jumps; $3 Million Deal Looms

Co-Diagnostics Jumps; $3 Million Deal Looms

20 May 2026
Co-Diagnostics announced a $3 million private placement after its stock surged 43.8% Tuesday, then fell 13.3% in after-hours trading. The company will sell 1.65 million shares or pre-funded warrants, plus warrants for up to 3.29 million more shares, nearly doubling its share count. The move follows its completion of a Bundibugyo virus assay as Ebola spreads in Congo and Uganda. Co-Diagnostics reported $8.2 million in cash at March 31.
Micron Stock Just Dodged the Nasdaq Selloff. A Samsung Strike Could Be Its Next Jolt

Micron Stock Just Dodged the Nasdaq Selloff. A Samsung Strike Could Be Its Next Jolt

20 May 2026
Micron Technology shares rose 2.5% Tuesday to $698.74, lifting its market value near $798 billion as the Nasdaq fell. Analysts cited tight memory supply and strong DRAM and NAND pricing. A planned strike by 48,000 Samsung workers Thursday could disrupt global memory supply, potentially raising prices. Micron recently sampled 256GB DDR5 server modules to partners.
Go toTop